DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the ...

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...